Maciej Gasior

August 20, 2020

Maciej Gasior, M.D., Ph.D., joined Marinus as vice president, clinical development in 2018. Dr. Gasior has nearly 15 years of pharmaceutical experience.

Prior to joining Marinus, he served as a senior medical director at TEVA Pharmaceuticals, where he led several R&D projects in the company’s pain portfolio that led to a regulatory approval. Other prior positions were with Bristol-Myers Squibb (Exploratory Clinical and Translational Research in Neuroscience and Pain) and Cephalon Inc. (Discovery and Clinical Research in CNS and Pain). Within these positions, Dr. Gasior was responsible for the clinical development and execution of global clinical programs and trials from Phases 1 through 4. Dr. Gasior is a former staff scientist in the Epilepsy Research Section (NIH-NINDS), junior faculty fellow at the Alcohol and Drug Abuse Research Center (Harvard Medical School) and post-doctoral fellow at the Drug Development Group (NIH-NIDA).

Dr. Gasior’s main research interests and expertise are in epilepsy, pain, and drug development for neuropsychiatric disorders. He has published over 90 papers in peer-reviewed journals, serves as a member of editorial boards for the Journal of Translational Neuroscience and Journal of CNS & Neurological Disorders – Drug Targets. He is also an adjunct professor of the Department of Pharmacology and Physiology (Drexel University College of Medicine). Dr. Gasior earned his M.D. with honors and Ph.D. in neuropharmacology from the Medical University of Lublin, Poland, where he is a full professor.